Oramed Pharmaceuticals (ORMP) News Today $2.15 +0.04 (+1.90%) Closing price 04:00 PM EasternExtended Trading$2.14 -0.01 (-0.47%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ORMP Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Oramed Pharm Extends Stock Buyback ProgramMay 21 at 4:53 PM | tipranks.comOramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.comStockNews.com cut Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday.May 19 at 3:18 AM | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Rating Lowered to Sell at StockNews.comMay 19 at 1:25 AM | americanbankingnews.comThe past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitableMay 17, 2025 | finance.yahoo.comStockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to SellStockNews.com cut Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday.May 11, 2025 | marketbeat.comOramed Pharmaceuticals (ORMP) to Release Earnings on ThursdayOramed Pharmaceuticals (NASDAQ:ORMP) will be releasing earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-oramed-pharmaceuticals-inc-stock/)May 3, 2025 | marketbeat.comOramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau MedicalApril 28, 2025 | finanznachrichten.deOramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau MedicalApril 28, 2025 | prnewswire.comAlpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed PharmaceuticalsApril 28, 2025 | globenewswire.comOramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Crosses Below 200-Day Moving Average - Here's WhyOramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Below 200-Day Moving Average - What's Next?April 25, 2025 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Below Two Hundred Day Moving Average - Time to Sell?Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Crosses Below 200 Day Moving Average - What's Next?April 16, 2025 | marketbeat.comQ1 Earnings Estimate for ORMP Issued By Zacks Small CapOramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - Research analysts at Zacks Small Cap issued their Q1 2025 EPS estimates for Oramed Pharmaceuticals in a report issued on Thursday, April 3rd. Zacks Small Cap analyst M. Marin anticipates that the biotechnology company will earn ($0.01) perApril 8, 2025 | marketbeat.comORMP: Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 TrialApril 3, 2025 | finance.yahoo.comOramed Pharmaceuticals (NASDAQ:ORMP) Announces Quarterly Earnings ResultsOramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.04.March 29, 2025 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Crosses Below Two Hundred Day Moving Average - Time to Sell?Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Below 200-Day Moving Average - Should You Sell?March 26, 2025 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell?Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Crosses Below Two Hundred Day Moving Average - Here's WhyMarch 18, 2025 | marketbeat.comOramed Pharmaceuticals And 2 Other Penny Stocks With Promising PotentialMarch 15, 2025 | finance.yahoo.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Stock Holdings Lifted by BML Capital Management LLCBML Capital Management LLC raised its position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 20.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,643,907 shares of the bioMarch 8, 2025 | marketbeat.comOramed Pharmaceuticals Issues Letter to ShareholdersMarch 4, 2025 | prnewswire.comOraMed Enters Global Licensing Deal for Lidocaine ProductMarch 1, 2025 | investing.comShort Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Expands By 149.0%Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) was the target of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 576,400 shares, an increase of 149.0% from the January 31st total of 231,500 shares. Based on an average daily trading volume, of 281,000 shares, the short-interest ratio is presently 2.1 days.March 1, 2025 | marketbeat.comCongressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals StockFebruary 27, 2025 | benzinga.comRep. Brad Knott Sells Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) SharesRepresentative Brad Knott (R-North Carolina) recently sold shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). In a filing disclosed on February 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Oramed Pharmaceuticals stock on January 10th. The trade occurred inFebruary 27, 2025 | marketbeat.comOramed Pharmaceuticals (ORMP) Projected to Post Quarterly Earnings on WednesdayOramed Pharmaceuticals (NASDAQ:ORMP) will be releasing earnings before the market opens on Wednesday, March 5, Financial Modeling Prep reports.February 26, 2025 | marketbeat.comPeapod Lane Capital LLC Invests $550,000 in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)Peapod Lane Capital LLC bought a new stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 227,239 shares of the biotechnology company's stock, valued at apFebruary 13, 2025 | marketbeat.comOraTech to pioneer oral insulin with $75 million investmentFebruary 11, 2025 | msn.comOramed enters JV for insulin development and commercializationFebruary 11, 2025 | markets.businessinsider.comOramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral InsulinFebruary 11, 2025 | prnewswire.comOramed Pharmaceuticals (NASDAQ:ORMP) Stock Crosses Below Two Hundred Day Moving Average - Should You Sell?Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Below 200-Day Moving Average - What's Next?February 8, 2025 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Rating Lowered to "Sell" at StockNews.comStockNews.com downgraded Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday.February 6, 2025 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Shares Cross Below Two Hundred Day Moving Average - Here's WhyOramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Crosses Below 200-Day Moving Average - Here's What HappenedJanuary 31, 2025 | marketbeat.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Significant Decrease in Short InterestOramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a significant decline in short interest in December. As of December 31st, there was short interest totalling 242,300 shares, a decline of 16.8% from the December 15th total of 291,400 shares. Based on an average daily volume of 144,800 shares, the days-to-cover ratio is currently 1.7 days.January 17, 2025 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Raised to Hold at StockNews.comStockNews.com upgraded Oramed Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Monday.January 13, 2025 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to "Hold" at StockNews.comStockNews.com raised Oramed Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Friday.December 27, 2024 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to Hold at StockNews.comStockNews.com raised Oramed Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday.December 18, 2024 | marketbeat.comScilex announces early installment payment on senior secured promissory noteDecember 16, 2024 | markets.businessinsider.comOramed Pharmaceuticals (NASDAQ:ORMP) Shares Cross Above Fifty Day Moving Average - Should You Sell?Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Crosses Above 50 Day Moving Average - Here's WhyDecember 13, 2024 | marketbeat.comORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent AgreementsDecember 2, 2024 | finance.yahoo.comOramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Below 200-Day Moving Average - Should You Sell?Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Crosses Below 200-Day Moving Average - What's Next?November 20, 2024 | marketbeat.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares Purchased by BML Capital Management LLCBML Capital Management LLC lifted its stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 62.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,186,191 shares of the biotecNovember 12, 2024 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Below 200 Day Moving Average - Here's What HappenedOramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Below 200 Day Moving Average - Time to Sell?November 6, 2024 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Buy at StockNews.comStockNews.com upgraded shares of Oramed Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday.October 22, 2024 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Cut to "Hold" at StockNews.comStockNews.com lowered shares of Oramed Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday.October 14, 2024 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to Buy by StockNews.comStockNews.com upgraded Oramed Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Friday.October 4, 2024 | marketbeat.comMurchinson Ltd. Raises Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)Murchinson Ltd. grew its position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 23.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,699,990 shares of the biotechnologySeptember 29, 2024 | marketbeat.comMurchinson Ltd. Trims Stock Holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)Murchinson Ltd. decreased its holdings in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 36.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 874,992 shares of the biotechnology company's stock aSeptember 24, 2024 | marketbeat.comQ3 2024 EPS Estimates for Oramed Pharmaceuticals Inc. Boosted by Analyst (NASDAQ:ORMP)Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - Investment analysts at HC Wainwright increased their Q3 2024 earnings per share estimates for Oramed Pharmaceuticals in a report issued on Monday, September 9th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology compaSeptember 11, 2024 | marketbeat.comOramed Pharm (ORMP) Receives a Hold from H.C. WainwrightSeptember 9, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Neutral" Rating for Oramed Pharmaceuticals (NASDAQ:ORMP)HC Wainwright reaffirmed a "neutral" rating on shares of Oramed Pharmaceuticals in a report on Monday.September 9, 2024 | marketbeat.comBrokers Offer Predictions for Oramed Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ORMP)Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - Investment analysts at Zacks Small Cap cut their Q3 2024 earnings per share estimates for Oramed Pharmaceuticals in a research report issued on Thursday, August 29th. Zacks Small Cap analyst M. Marin now expects that the biotechnology compSeptember 2, 2024 | marketbeat.com Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Email Address ORMP Media Mentions By Week ORMP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORMP News Sentiment▼-0.530.69▲Average Medical News Sentiment ORMP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORMP Articles This Week▼51▲ORMP Articles Average Week Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alpha Teknova News Today Checkpoint Therapeutics News Today Erasca News Today Humacyte News Today Cidara Therapeutics News Today Cryoport News Today Arcturus Therapeutics News Today Olema Pharmaceuticals News Today iTeos Therapeutics News Today Phathom Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORMP) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORMP Stock Free ORMP Stock Alerts